Soligenix published HyBryte versus Valchlor data in CTCL. Read what it changes for approval, adoption, and competitive positioning.
Accent Therapeutics is expanding the ATX-295 story in solid tumors. Read what the new AACR 2026 data could change and what risks remain.
Nuvation Bio now controls safusidenib globally. Read why the Japan deal matters for IDH1-mutant glioma, SIGMA, and the post-vorasidenib market.
Scinai Immunotherapeutics doubled CDMO revenue in 2025. Read what the Recipharm deal and PC111 focus could mean for its biotech strategy.
Better Life Science is pushing at-home Lyme testing this spring. Read what Tick Bite Hero changes, where it fits, and what risks remain.
Abbisko Therapeutics won EMA orphan drug designation for irpagratinib in liver cancer. Read what this changes for FGFR4-targeted therapy.
Tenpoint Therapeutics and PHIL launch YUVEZZI direct-to-patient access for presbyopia. Read what it means for affordability, uptake, and market adoption.
EarliPoint Health and Netsmart are expanding access to autism assessment technology. Read what this could change for providers, workflows, and adoption.
PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.
CTIS launches Trial SafetyXchange to help pharma firms meet the FDA E2B(R3) deadline. Read what it changes for safety reporting teams.